Literature DB >> 2858847

Tolerability of combined treatment with verapamil and beta-blockers in angina resistant to monotherapy.

J C McGourty, J H Silas, S A Solomon.   

Abstract

We have used a combination of a beta-blocker and verapamil to treat 42 consecutive patients with angina resistant to either agent alone. Patients with heart failure, heart block or uncontrolled hypertension were excluded. The mean duration of follow-up was 6.5 months. Thirty-six patients (81%) reported an improvement and the number of angina attacks was reduced from 17/week to 5/week. Side effects necessitated withdrawal of one or both drugs in 6 patients, 2 of whom developed bradyarrhythmias not solely related to drug treatment. The most common complication was mild left ventricular failure (6) treated by reducing or stopping the beta-blocker. The data suggest that the combination of verapamil and a beta-blocker may be used in a relatively unselected group of patients with difficult angina. However, as dosage adjustment and close observation may be necessary to minimise side effects, the use of this combination should be limited to hospital practice.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858847      PMCID: PMC2418202          DOI: 10.1136/pgmj.61.713.229

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  15 in total

1.  Nifedipine and beta-blocker drugs.

Authors:  C J Anastassiades
Journal:  Br Med J       Date:  1980-11-08

2.  The effects of intravenous verapamil on hemodynamic status of patients with coronary artery disease receiving propranolol.

Authors:  J Kieval; E B Kirsten; K M Kessler; S M Mallon; R J Myerburg
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

3.  Combined therapy with verapamil and propranolol in chronic stable angina.

Authors:  B Subramanian; M J Bowles; A B Davies; E B Raftery
Journal:  Am J Cardiol       Date:  1982-01       Impact factor: 2.778

4.  Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris.

Authors:  M B Leon; D R Rosing; R O Bonow; L C Lipson; S E Epstein
Journal:  Am J Cardiol       Date:  1981-07       Impact factor: 2.778

5.  Adverse interaction between nifedipine and beta-blockade.

Authors:  L H Opie; D A White
Journal:  Br Med J       Date:  1980-11-29

6.  Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man.

Authors:  M Packer; J Meller; N Medina; M Yushak; H Smith; J Holt; J Guererro; G D Todd; R G McAllister; R Gorlin
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

7.  Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris.

Authors:  S M Johnson; D R Mauritson; J R Corbett; W Woodward; J T Willerson; L D Hillis
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

8.  Additive antianginal effect of verapamil in patients receiving propranolol.

Authors:  M Bassan; D Weiler-Ravell; O Shalev
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-10

9.  Rationale for the choice of calcium antagonists in chronic stable angina. An objective double-blind placebo-controlled comparison of nifedipine and verapamil.

Authors:  V B Subramanian; M J Bowles; N S Khurmi; A B Davies; E B Raftery
Journal:  Am J Cardiol       Date:  1982-11       Impact factor: 2.778

10.  Nifedipine and left ventricular function in beta-blocked patients.

Authors:  P I Joshi; J J Dalal; M S Ruttley; D J Sheridan; A H Henderson
Journal:  Br Heart J       Date:  1981-04
View more
  7 in total

Review 1.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

2.  The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.

Authors:  J C McCourty; J H Silas; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

3.  Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man.

Authors:  A C Keech; R W Harper; P M Harrison; A Pitt; A J McLean
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 5.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

6.  The effects of oral nitrendipine and propranolol, alone and in combination, on hypertensive patients with special reference to AV conduction.

Authors:  M B Maltz; D W Davies; C P Lau; J E Creamer; S O Banim; A J Camm
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

7.  A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris.

Authors:  I N Findlay; K MacLeod; G Gillen; A T Elliott; T Aitchison; H J Dargie
Journal:  Br Heart J       Date:  1987-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.